Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exper Med Biol 2014;825:303-52.Rigo, F., Seth, P.P. and Bennett, C.F. (2014) Antisense oligo- nucleotide-based therapies for diseases caused by pre- mRNA processing defects. Adv. Exp. Med. ...
当当中国进口图书旗舰店在线销售正版《【预订】Oligonucleotide-Based Therapies 9781493996728》。最新《【预订】Oligonucleotide-Based Therapies 9781493996728》简介、书评、试读、价格、图片等相关信息,尽在DangDang.com,网购《【预订】Oligonucleotide-Based Therap
Pañeda C, Martinez T, Wright N, Jimenez A (2012) Recent advances in ocular nucleic-based therapies: the silent era. In: Adio A (ed) Ocular diseases. InTech, pp 157–185 Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: challenges ...
oligonucleotide drug delivery ; pre-clinical safety evaluation of antisense oligonucleotide drugs ; medicinal chemistry of nucleic acids ; targeting protein kinases ; antisense oligonucleotide drug discovery case studies ; antisense therapeutics ; human gene therapy ; advances in pharmaceutical therapies ;声明...
We also address potential roadblocks in the clinical translation of ASO-based therapies for the treatment of OA, such as the limitations associated with OA animal models and the challenges with drug toxicity. Taken together, we review what is known and what would be useful to accelerate ...
Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet. 2013;132: 481-93.Martinez T, Wright N, Lopez-Fraga M, Jimenez AI, Paneda C. Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet 2013; 132: 481-493....
Silencing human genetic diseases with oligonucleotide-based therapies[J] . Tamara Martínez,Natalia Wright,Marta López-Fraga,Ana Isabel Jiménez,Covadonga Pa?eda.Human Genetics . 2013 (5)Martinez T, Wright N, Lopez-Fraga M, Jimenez A, Pan~eda C. Silencing human genetic diseases with ...
Design of Preclinical Safety and Efficacy Studies: The Basics of Cell, Gene, and Oligonucleotide-Based TherapiesCavagnaro, Joy
Design of new oligonucleotide-based antigene and antisensetherapiesModesto Orozco López
Conventional cancer therapies remain of limited use in treating the majority of common solid tumors. Patients with lung, breast, colonic, and pancreatic cancers, which cannot be surgically removed, will almost certainly develop metastatic spread of their disease and die. The treatment prospects for ...